{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:21:21Z","timestamp":1767903681333,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jmmc-online.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.yjmcc.2015.06.018","type":"journal-article","created":{"date-parts":[[2015,7,2]],"date-time":"2015-07-02T23:44:05Z","timestamp":1435880645000},"page":"12-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Losartan: A new treatment for cardiac cachexia?"],"prefix":"10.1016","volume":"86","author":[{"given":"Marielle","family":"Scherrer-Crosbie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yjmcc.2015.06.018_bb0005","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","article-title":"Mechanisms of cancer cachexia","volume":"89","author":"Tisdale","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0010","doi-asserted-by":"crossref","first-page":"693458-7","DOI":"10.1155\/2009\/693458","article-title":"Estimation of cachexia among cancer patients based on four definitions","volume":"2009","author":"Fox","year":"2009","journal-title":"J. Oncol."},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0015","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0020","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/MCO.0b013e328300ecc1","article-title":"Cachexia: prevalence and impact in medicine","volume":"11","author":"Tan","year":"2008","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0025","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/eurheartj\/eht302","article-title":"Prevention of liver cancer cachexia-induced cardiac wasting and heart failure","volume":"35","author":"Springer","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0030","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ajpath.2010.12.009","article-title":"NF-\u03baB inhibition protects against tumor-induced cardiac atrophy in vivo","volume":"178","author":"Wysong","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0035","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.lfs.2010.12.010","article-title":"Myocardial dysfunction in an animal model of cancer cachexia","volume":"88","author":"Xu","year":"2011","journal-title":"Life Sci."},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0040","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/MAJ.0b013e318222e620","article-title":"Angiotensin II, oxidative stress and skeletal muscle wasting","volume":"342","author":"Sukhanov","year":"2011","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0045","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bjc.6602725","article-title":"Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia","volume":"93","author":"Sanders","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0050","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1210\/endo.142.4.8082","article-title":"Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I","volume":"142","author":"Brink","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0055","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1172\/JCI118698","article-title":"Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism","volume":"97","author":"Brink","year":"1996","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.yjmcc.2015.05.007","article-title":"Losartan treatment attenuates tumor-induced myocardial dysfunction","volume":"85","author":"Stevens","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0065","doi-asserted-by":"crossref","first-page":"F1260","DOI":"10.1152\/ajprenal.00069.2014","article-title":"Modulation of angiotensin II-induced inflammatory cytokines by the Epac1\u2013Rap1A\u2013NHE3 pathway: implications in renal tubular pathobiology","volume":"306","author":"Xie","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0070","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/hc1102.105258","article-title":"Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure","volume":"105","author":"Loennechen","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0075","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/carcin\/bgn171","article-title":"The renin\u2013angiotensin system and malignancy","volume":"29","author":"Ager","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0080","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tem.2005.07.009","article-title":"Angiotensin receptors: a new role in cancer?","volume":"16","author":"Deshayes","year":"2005","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"Lever","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0090","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/pros.10294","article-title":"Association between captopril, other antihypertensive drugs and risk of prostate cancer","volume":"58","author":"Ronquist","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0095","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2006.06.028","article-title":"ACE inhibitors may reduce esophageal cancer incidence","volume":"131","author":"Lang","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0100","first-page":"1139","article-title":"Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor","volume":"2","author":"Uemura","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.yjmcc.2015.06.018_bb0105","first-page":"1","article-title":"Angiotensin II, receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling","volume":"27","author":"Ren","year":"2012","journal-title":"Oncol. Rep."}],"container-title":["Journal of Molecular and Cellular Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282815300031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282815300031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T01:58:42Z","timestamp":1537495122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022282815300031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":21,"alternative-id":["S0022282815300031"],"URL":"https:\/\/doi.org\/10.1016\/j.yjmcc.2015.06.018","relation":{},"ISSN":["0022-2828"],"issn-type":[{"value":"0022-2828","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Losartan: A new treatment for cardiac cachexia?","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yjmcc.2015.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}